OBJECTIVE: The purpose of this study was to examine psychiatrists' attitudes and practices in prescribing second-generation antipsychotics (SGA) to children and adolescents (referred to here as "children") and identify factors associated with off-label SGA use. METHODS: A survey was mailed to a national, randomly selected sample of 1600 child and adolescent psychiatrists identified by the American Medical Association. Multivariable logistic regression was used to identify factors, including psychiatrists' characteristics, practice characteristics, and psychiatrists' attitudes, that are associated with off-label SGA use (i.e., SGAs used in children with attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, conduct disorder, or nonbipolar mood disorders). RESULTS: The final sample included 340 psychiatrists. Overall, respondents reported higher use and appropriateness of SGAs for United States Food and Drug Administration (FDA)-approved disorders, symptoms of aggression, and older child age. More than one third (36%) of respondents reported some off-label SGA use. Significant predictors of off-label use were: Practicing at inpatient/residential facilities (odds ratio [OR]=4.2, p=0.001); white/non-Hispanic race/ethnicity (OR=0.3, p<0.0001), agreeing that SGAs should be used for ADHD with aggression (OR=7.1, p<0.0001); and agreeing that SGAs should be used for severe delinquent behaviors (OR=1.9, p=0.03). CONCLUSIONS: Psychiatrists' attitudes about prescribing SGAs to children exhibiting aggressive symptoms were associated with off-label SGA use. Research is needed to understand the construct of aggression, potential interaction effects of aggression with diagnostic criteria, and their impact on SGA use.
OBJECTIVE: The purpose of this study was to examine psychiatrists' attitudes and practices in prescribing second-generation antipsychotics (SGA) to children and adolescents (referred to here as "children") and identify factors associated with off-label SGA use. METHODS: A survey was mailed to a national, randomly selected sample of 1600 child and adolescent psychiatrists identified by the American Medical Association. Multivariable logistic regression was used to identify factors, including psychiatrists' characteristics, practice characteristics, and psychiatrists' attitudes, that are associated with off-label SGA use (i.e., SGAs used in children with attention-deficit/hyperactivity disorder (ADHD), oppositional defiant disorder, conduct disorder, or nonbipolar mood disorders). RESULTS: The final sample included 340 psychiatrists. Overall, respondents reported higher use and appropriateness of SGAs for United States Food and Drug Administration (FDA)-approved disorders, symptoms of aggression, and older child age. More than one third (36%) of respondents reported some off-label SGA use. Significant predictors of off-label use were: Practicing at inpatient/residential facilities (odds ratio [OR]=4.2, p=0.001); white/non-Hispanic race/ethnicity (OR=0.3, p<0.0001), agreeing that SGAs should be used for ADHD with aggression (OR=7.1, p<0.0001); and agreeing that SGAs should be used for severe delinquent behaviors (OR=1.9, p=0.03). CONCLUSIONS: Psychiatrists' attitudes about prescribing SGAs to children exhibiting aggressive symptoms were associated with off-label SGA use. Research is needed to understand the construct of aggression, potential interaction effects of aggression with diagnostic criteria, and their impact on SGA use.
Authors: Sarah B Schur; Lin Sikich; Robert L Findling; Richard P Malone; M Lynn Crismon; Albert Derivan; James C Macintyre Ii; Elizabeth Pappadopulos; Laurence Greenhill; Nina Schooler; Kimberly Van Orden; Peter S Jensen Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-02 Impact factor: 8.829
Authors: Penelope Knapp; Alanna Chait; Elizabeth Pappadopulos; Stephen Crystal; Peter S Jensen Journal: Pediatrics Date: 2012-05-28 Impact factor: 7.124
Authors: Michael L Birnbaum; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; John M Kane; Christoph U Correll Journal: Curr Psychiatry Rep Date: 2013-08 Impact factor: 5.285
Authors: Elizabeth Pappadopulos; Nancy Scotto Rosato; Christoph U Correll; Robert L Findling; Judith Lucas; Stephen Crystal; Peter S Jensen Journal: J Child Adolesc Psychopharmacol Date: 2011-12 Impact factor: 2.576
Authors: Peter S Jensen; Eric A Youngstrom; Hans Steiner; Robert L Findling; Roger E Meyer; Richard P Malone; Gabrielle A Carlson; Emil F Coccaro; Michael G Aman; James Blair; Donald Dougherty; Craig Ferris; Laurie Flynn; Evelyn Green; Kimberly Hoagwood; Janice Hutchinson; Tom Laughren; Leslie D Leve; Douglas K Novins; Benedetto Vitiello Journal: J Am Acad Child Adolesc Psychiatry Date: 2007-03 Impact factor: 8.829
Authors: Stephen Crystal; Mark Olfson; Cecilia Huang; Harold Pincus; Tobias Gerhard Journal: Health Aff (Millwood) Date: 2009-07-21 Impact factor: 6.301
Authors: Elizabeth Pappadopulos; James C Macintyre Ii; M Lynn Crismon; Robert L Findling; Richard P Malone; Albert Derivan; Nina Schooler; Lin Sikich; Laurence Greenhill; Sarah B Schur; Chip J Felton; Harvey Kranzler; David M Rube; Jeffrey Sverd; Molly Finnerty; Scott Ketner; Sonja E Siennick; Peter S Jensen Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-02 Impact factor: 8.829
Authors: Angie Mae Rodday; Susan K Parsons; Catherine Mankiw; Christoph U Correll; Adelaide S Robb; Bonnie T Zima; Tully S Saunders; Laurel K Leslie Journal: J Child Adolesc Psychopharmacol Date: 2015-04-28 Impact factor: 2.576
Authors: Luuk J Kalverdijk; Christian J Bachmann; Lise Aagaard; Mehmet Burcu; Gerd Glaeske; Falk Hoffmann; Irene Petersen; Catharina C M Schuiling-Veninga; Linda P Wijlaars; Julie M Zito Journal: Child Adolesc Psychiatry Ment Health Date: 2017-10-11 Impact factor: 3.033